Eagle Genomics raises £6.9m in Series A funding led by Granpool Innovative Investments to expand platform capabilities
Granpool Innovative Investments and Environmental Technologies Fund backed the round, which will support global expansion and technology development.
Eagle Genomics operates a pioneering TechBio platform that applies network science and artificial intelligence to biological data. The company helps global enterprises accelerate sustainable product innovation across food, agriculture, beauty, and biopharma industries.
Eagle Genomics has secured £6.9m in a Series A funding round led by Granpool Innovative Investments. The round saw participation from Environmental Technologies Fund and a consortium including bpd partners, Anatom Holding, and Albert-László Barabási.
The capital will be used to enhance the capabilities of the company's AI-augmented platform and to drive commercial expansion across Europe and the United States. This follows rising demand from enterprise organisations seeking to harness genomic data for product innovation in food, agriculture, and wellness.
The investment underscores growing market interest in microbiome-related research as major consumer brands increasingly look to substantiate biological claims for their products.
From the founder
"The microbiome is a megatrend that is evolving very quickly, and we are the forefront of associated discovery with our unique solution to address the enterprise data challenge. We have our sights set too on other complex data challenges including CRISPR and quantum biological challenges, such as understanding the immune response more fully. The potential is phenomenal, and we are immensely grateful to our supporters for sharing our vision and helping us to scale at this pivotal time."
Anthony Finbow
CEO at Eagle Genomics
Investor perspective
"We are delighted to see Eagle Genomics go from strength to strength, and to be able to support this crucial next stage of growth. The timing could not be better, with the world's focus on disease and accelerated innovation and ever more in-silico innovation. We wish the team all the best in expanding its reach and deepening its capabilities."
Rob Genieser
Environmental Technologies Fund
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Granpool Innovative Investments
Rob Genieser
Environmental Technologies Fund
bpd partners
Anatom Holding
Albert-László Barabási
Albert-László Barabási
Categories
About the company
Eagle Genomics
Eagle Genomics develops an AI-augmented knowledge discovery platform for biological and microbiome data analysis.